News | Heart Valve Technology | October 31, 2017

Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients

Lower costs with transcatheter valve driven by shorter lengths of stay, simpler procedures, fewer hospitalizations and rehab days

Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients

October 31, 2017 — Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

The economic analysis of the SAPIEN 3 valve compared to surgery involved more than 2,000 patients enrolled in both the PARTNER IIA Trial and the SAPIEN 3 intermediate risk trial. The analysis showed significantly lower total one-year costs, on average, with the Sapien 3 valve compared with surgical aortic valve replacement ($80,977 versus $96,489). Average index hospitalization costs — which include the costs of the procedure, hospital stay and physician fees — were also lower with the Sapien 3 valve versus surgery ($54,256 vs. $58,410). Reduced length of stay, simpler, more efficient procedures, fewer repeat hospitalizations and less time in rehabilitation contributed to the economically dominant results of the Sapien 3 valve. Transcatheter aortic valve replacement (TAVR) with the Sapien 3 valve added 0.27 quality-adjusted life years (QALY) per patient at a lifetime cost savings of approximately $10,000 compared with surgery. The SAPIEN 3 intermediate risk trial enrolled patients during 2014.

"Based on both clinical and economic considerations, these findings demonstrate that TAVR should be the preferred strategy for patients with severe aortic stenosis at intermediate surgical risk," said David J. Cohen, M.D., professor of medicine at the University of Missouri-Kansas City and director of cardiovascular research at Saint Luke's Mid America Heart Institute, who presented the study results. "Taken together with previous data demonstrating excellent clinical outcomes and significantly improved quality of life with TAVR, this latest study shows that TAVR with the Sapien 3 valve also provides important short and long-term economic advantages compared with surgery."

The researchers also performed an analysis of the Sapien XT valve compared with surgery, using data from the randomized PARTNER II A Trial on 1,938 patients enrolled from 2011 to 2013. According to the researchers, over a lifetime, TAVR with the Sapien XT valve was also projected to be an economically dominant strategy, providing both greater quality-adjusted life expectancy and lower long-term costs than surgery, with a high degree of confidence. The Sapien XT valve is no longer utilized in clinical practice in the United States; instead, the next-generation Sapien 3 is utilized in the U.S. and most other geographies worldwide.

The Sapien 3 valve was approved by the U.S. Food and Drug Administration (FDA) in 2015 for severe, symptomatic aortic stenosis patients at high risk for open-heart surgery, and, in 2016, received approval for the treatment of patients who are at intermediate risk for open-heart surgery.

Cohen is a consultant to Edwards Lifesciences. The PARTNER II Trial was sponsored by Edwards Lifesciences.

For more information: www.tctconference.com

Related TCT Content

TCT Announces 2017 Late-breaking Clinical Trial Presentations

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init